The European Commission has approved JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally ...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 4, 2014 /PRNewswire/ -- The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data ...

First DPP-4 inhibitor approved at one dosage strength; no dose adjustment recommended for patients with type 2 diabetes who have kidney or liver impairment RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, ...

The new diabetes test helps identify patients with type 1 diabetes The FDA has approved empagliflozin/linagliptin tablets as an adjunct to diet and exercise to ...

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--EX US, UK and UAE Medical Media Only. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a 24-week open label arm ...

TRADJENTA (linagliptin) 5mg tablets by Boehringer Ingelheim and Eli Lilly Boehringer Ingelheim and Eli Lilly announced that the FDA has approved Tradjenta (linagliptin tablets), a dipeptidyl peptidase ...

The recommendation for approval of linagliptin/metformin HCl tablets was based on clinical trials that evaluated linagliptin and metformin as separate tablets. Bioequivalence of linagliptin/metformin ...

The FDA has approved Tradjenta (linagliptin) tablets to control blood sugar in adults with diabetes type two – to be used along with diet and exercise, Boehringer Ingelheim Pharmaceuticals, Inc. and ...

Glyxambi Approved for Type 2 Diabetes The Food and Drug Administration (FDA) has approved Glyxambi (empagliflozin/linagliptin tablets; Boehringer Ingelheim and Eli ...